Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

NCT06075953 is registered in ClinicalTrials.gov with QuantumLeap Healthcare Collaborative as lead sponsor.

NCT NCT06075953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study
Lead sponsor
QuantumLeap Healthcare Collaborative
Phase
Phase 2
Overall status
Recruiting
Start date
February 17, 2024
Completion date
November 30, 2033
Enrollment
400 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

ductal carcinoma in situ